首页|肝细胞癌组织中PRDX4,GRAMD1A水平表达与临床病理特征及预后的关系研究

肝细胞癌组织中PRDX4,GRAMD1A水平表达与临床病理特征及预后的关系研究

Study on the Relationship among the Expression of PRDX4 and GRAMD1A Levels in Hepatocellular Carcinoma Tissues with Clinicopathologic Features and Prognosis

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
目的 探究肝细胞癌(hepatocellular carcinoma,HCC)组织中过氧化物还原酶4(peroxiredoxin 4,PRDX4),GRAM结构域蛋白1A(GRAM domain-containing protein 1A,GRAMD1A)的水平表达,并分析二者与临床病理特征及预后的关系.方法 收集巴中市中心医院2017年5月～2020年5月收治的136例肝细胞癌患者作为研究对象,术中取癌组织与癌旁组织,采用免疫组织化学法测定肝细胞癌组织与癌旁组织中PRDX4和GRAMD1A的表达,Kaplan-Meier生存曲线分析PRDX4和GRAMD1A表达与肝细胞癌患者生存率的关系,COX回归模型分析肝细胞癌患者预后的影响因素.结果 肝细胞癌组织PRDX4[69.12％(94/136)]和GRAMD1A阳性表达率[58.82％(80/136)]高于癌旁组织[7.35％(10/136),18.38％(25/136)],差异具有统计学意义(x2=109.846,46.923,均 P＜0.05).TNM 分期为 Ⅲ期+Ⅳ期、组织分化程度低分化、肿瘤多发、HBsAg阳性的肝细胞癌患者PRDX4和GRAMD1A阳性表达比例显著高于TNM分期为Ⅰ期+Ⅱ期、组织分化程度高/中分化、肿瘤少发、HBsAg阴性的肝细胞癌患者,差异具有统计学意义(x2=12.273,16.359,10.004,5.485;23.217,24.461,18.651,8.594,均 P＜0.05);肝细胞癌组织 PRDX4 阳性表达患者的三年生存率[43.62％(41/94)]低于PRDX4阴性表达患者[73.81％(31/42)],肝细胞癌组织GRAMD1A阳性表达患者三年生存率[46.25％(37/80)]低于GRAMD1A阴性表达患者[62.50％(35/56)],差异具有统计学意义(x2=12.965,7.475,均P＜0.05);TNM分期、肿瘤数量、HBsAg,PRDX4和GRAMD1A表达是影响肝细胞癌患者死亡的独立危险因素(均P＜0.05).结论 肝细胞癌组织中PRDX4和GRAMD1A阳性率升高,与患者预后不良密切相关,二者可作为肝细胞癌诊断和预后评估的生物标记物.
Objective To investigate the expression of peroxiredoxin 4(PRDX4)and GRAM domain-containing protein 1A(GRAMD1A)levels in hepatocellular carcinoma(HCC)tissue and analyze their relationship with clinical pathological characteristics and prognosis.Methods A total of 136 patients with HCC admitted to Bazhong Central Hospital from May 2017 to May 2020 were regarded as research subjects.Cancer tissue and adjacent tissue were taken during surgery.Immunohistochemical method was applied to determine the expression of PRDX4 and GRAMD1A in HCC tissues and adjacent tissues.Kaplan-Meier survival curve was applied to analyze the relationship between PRDX4 and GRAMD1A expression and survival rate in HCC patients.COX regression model was applied to analyze the prognostic factors of HCC patients.Results The positive expression rates of PRDX4[69.12％(94/136)]and GRAMD1A[58.82％(80/136)]in HCC tissues were higher than those in adjacent tissues[7.35％(10/136),18.38％(25/136)],with significant differences(x2=109.846,46.923,all P＜0.05).The positive expression rates of PRDX4 and GRAMD1A in HCC patients with TNM stage Ⅲ+Ⅳ,low tissue differentiation,multiple tumors,and HBsAg positive were higher than those in HCC patients with TNM stage Ⅰ+Ⅱ,high/medium tissue differentiation,fewer tumors,and HBsAg negative(x2=12.273,16.359,10.004,5.485;23.217,24.461,18.651,8.594,all P＜0.05).The 3-year survival rate of patients with PRDX4 positive expression[43.62％(41/94)]in HCC tissue was lower than that of patients with PRDX4 negative expression[73.81％(31/42)],the 3-year survival rate of GRAMD1A positive expression patients[46.25％(37/80)]was lower than that of GRAMD1A negative expression patients[62.50％(35/56)],and the differences were statistically significant(x2=12.965,7.475,all P＜0.05).TNM staging,tumor number,HBsAg,PRDX4,and GRAMD1A expression were independent risk factors for mortality in HCC patients(P＜0.05).Conclusion The positive rates of PRDX4 and GRAMD1A were increased in HCC tissues,and they were closely related to the poor prognosis of patients.Both of them may be used as biomarkers for diagnosis and prognosis evaluation of HCC.

hepatocellular carcinomaperoxiredoxin 4GRAM domain-containing protein 1A

赵倩、冯娇

展开 >

巴中市中心医院检验科,四川巴中 636600

肝细胞癌 过氧化物还原酶4 GRAM结构域蛋白1A

2024

10.3969/j.issn.1671-7414.2024.03.020

现代检验医学杂志
陕西省临床检验中心,陕西省人民医院

现代检验医学杂志

CSTPCD
影响因子：0.713
ISSN：1671-7414
年,卷(期)：2024.39(3)